Evidence map›Paper›PMID 42393056›Full record

ArticleBlood cancer journal2026

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Karan L Chohan, Eduardo Edelman Saul, R Eric Davis, Fredrick Hagemeister, Raphael Steiner, Luis Fayad, Sairah Ahmed, Alma Rodriguez, Swaminathan P Iyer, Ranjit Nair and 15 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Karan L Chohan *Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1239-074X
Eduardo Edelman Saul *Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R Eric DavisDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7311-0065
Fredrick HagemeisterDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Raphael SteinerDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3717-3629
Luis FayadDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sairah AhmedDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7302-8299
Alma RodriguezDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3564-8697
Swaminathan P IyerDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ranjit NairDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francisco VegaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5956-452X
Dai ChiharaDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1153-2294
Paolo StratiDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7445-1459
Preetesh JainDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2735-168X
Luis Malpica CastilloDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chijioke NzeDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fateeha FurqanDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ayushi ChauhanDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark P HamiltonDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jared HendersonDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5121-5234
Anath C LionelDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher R FlowersDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9524-3990
Sattva NeelapuDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1045-4914
Michael R GreenDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6309-9472
Jason WestinDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwestin@mdanderson.org.ORCID http://orcid.org/0000-0002-1824-2337

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42393056
PMCPMC13328379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.